1.83
+0.05(+2.81%)
Currency In USD
| Previous Close | 1.78 |
| Open | 1.8 |
| Day High | 1.93 |
| Day Low | 1.77 |
| 52-Week High | 17.19 |
| 52-Week Low | 0.61 |
| Volume | 711,105 |
| Average Volume | 1.08M |
| Market Cap | 296.36M |
| PE | -1.17 |
| EPS | -1.57 |
| Moving Average 50 Days | 1.71 |
| Moving Average 200 Days | 1.89 |
| Change | 0.05 |
If you invested $1000 in Neumora Therapeutics, Inc. Common Stock (NMRA) since IPO date, it would be worth $112.62 as of October 04, 2025 at a share price of $1.83. Whereas If you bought $1000 worth of Neumora Therapeutics, Inc. Common Stock (NMRA) shares 1 year ago, it would be worth $123.98 as of October 04, 2025 at a share price of $1.83.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Neumora Therapeutics to Host Virtual R&D Day on October 27
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad r
Neumora Therapeutics to Participate in Upcoming Conferences in September
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
GlobeNewswire Inc.
Jul 23, 2025 11:00 AM GMT
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage program